Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate

Oncology Letters

Volumn 7, Issue 4, 2014, Pages 1151-1158

  Lin, Lilie L ^a   Mick, Rosemarie ^b   Ware, Jeffrey ^a   Metz, James ^a   Lustig, Robert ^a   Vapiwala, Neha ^a   Rengan, Ramesh ^a   Kennedy, Ann R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bowman Birk inhibitor; Bowman Birk inhibitor concentrate; Cancer prevention; Soybean

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOWMAN BIRK INHIBITOR; HEMOGLOBIN; MONOCLONAL ANTIBODY; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PREVENTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOT HYBRIDIZATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; LEUKOCYTOSIS; MALE; MIDDLE AGED; MOUTH INFECTION; NEOPLASM; NORMAL HUMAN; ORANGE JUICE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; X RAY; YOUNG ADULT;

EID: 84896712210     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1855     Document Type: Article

References (32)

1. Messina MJ, Persky V, Setchell KD and Barnes S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21: 113-131, 1994.
2. Kennedy AR: The evidence for soybean products as cancer preventive agents. J Nutr 125 (3 Suppl): 733S-743S, 1995.
3. Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther 78: 167-209, 1998.
4. Larionova NI, Gladysheva IP, Tikhonova TV and Kazanskaia NF: Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor. Biokhimiia 58: 1437-1444, 1993 (In Russian).
5. Tikhonova TV, Gladysheva IP, Kazanshaya NF and Larionova NI: Inhibition of elastin hydrolysis, catalyzed by human leukocyte elastase and cathepsin G, by the Bowman-Birk type soy inhibitor. Biokhimiia 59: 1739-1745, 1994 (In Russian).
6. Gladysheva IP, Larionova NI, Gladyshev DP, Tikhonova TV and Kazanskaia NF: The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G. Biokhimiia 59: 513-518, 1994 (In Russian).
7. Ware JH, Wan XS, Rubin H, Schechter NM and Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344: 133-138, 1997.
8. Kennedy AR: Cancer prevention by protease inhibitors. Prev Med 22: 796-811, 1993.
9. Kennedy AR: Anticarcinogenic activity of protease inhibitors: Overview. In: Protease Inhibitors as Cancer Chemopreventive Agents. Troll W and Kennedy AR (eds). 1st edition. Plenum Press, New York, pp9-64, 1993.
10. Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther 78: 167-209, 1998.
11. Kennedy AR, Szuhaj BF, Newberne PM and Billings PC: Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19: 281-302, 1993.
12. Kennedy AR: In vitro studies of anticarcinogenic protease inhibitors. In: Protease Inhibitors as Cancer Chemopreventive Agents. Troll W and Kennedy AR (eds). 1st edition. Plenum Press, New York, pp65-91, 1993.
13. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE and Meyskens FL Jr: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9: 43-47, 2000.
14. Malkowicz SB, McKenna WG, Vaughn DJ, et al: Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 48: 16-28, 2001.
15. Armstrong WB, Kennedy AR, Wan XS, et al: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6: 4684-4691, 2000.
16. Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR and Ware JH: Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci 53: 175-180, 2008.
17. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
18. Wan XS, Koch CJ, Lord EM, et al: Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor. J Immunol Methods 180: 117-130, 1995.
19. Furuya Y, Cho S, Ohta S, Sato N, Kotake T and Masai M: High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer. J Urol 166: 213, 2001.
20. Fleseriu M, Lee M, Pineyro MM, et al: Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. J Neurooncol 79: 41-43, 2006.
21. McCudden CR, Voorhees PM and Hammett-Stabler CA: A case of hook effect in the serum free light chain assay using the Olympus AU400e. Clin Biochem 42: 121-124, 2009.
22. Meyskens FL Jr, Armstrong WB, Wan XS, et al: Bowman-Birk inhibitor concentrate (BBIC) affects oral leukoplakia lesion size, neu protein levels and proteolytic activity in buccal mucosal cells. Proc. Am. Assoc. Cancer Res. 40: Abstract #2855, 1999.
23. Wan XS, Meyskens FL, Jr, Armstrong WB, Taylor TH and Kennedy AR: Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Cancer Epidemiol Biomark Prev 8: 601-608, 1999.
24. Malkowicz SB, Broderick GA, Zoltick B, et al: Phase I study of oral Bowman-Birk inhibitor concentrate (BBIC), a soy protein, on patients with lower urinary tract symptoms. J Urol 161: 228, 1999.
25. Billings PC, Brandon DL and Habres JM: Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer 27: 903-908, 1991.
26. Billings PC, St Clair WH, Maki PA and Kennedy AR: Distribution of the Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett 62: 191-197, 1992.
27. Yavelow J, Finlay TH, Kennedy AR and Troll W: Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 43 (5 Suppl): 2454s-2459s, 1983.
28. Brandon DL, Bates AH and Friedman M: Monoclonal antibody-based enzyme immunoassay of the Bowman-Birk protease inhibitor of soybeans. J Agric Food Chem 37: 1192-1196, 1989.
29. Brandon DL, Bates AH and Friedman M: ELISA analysis of soybean trypsin inhibitors in processed foods. Adv Exp Med Biol 289: 321-337, 1991.
30. Brandon DL: Antigenicity of soybean protease inhibitors. In: Protease inhibitors as Cancer Chemopreventive agents. Troll W, Kennedy, A. R. (ed) 1st edition. Plenum Press, New York, pp107-129, 1993.
31. Wan XS, Lu LJ, Anderson KE, Ware JH and Kennedy AR: Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay. Cancer Epidemiol Biomark Prev 9: 741-747, 2000.
32. Kennedy AR: The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68 (6 Suppl): 1406S-1412S, 1998.